FORT MYERS, Florida, July 2, 2026
Trilogy Laboratories has announced the acquisition of YNS Cosmeceuticals, a respected skincare brand recognized for its simple and effective approach to healthy skin. The acquisition brings together YNS Cosmeceuticals’ established skincare philosophy with Trilogy Laboratories’ pharmaceutical formulation expertise, FDA-registered cosmetic manufacturing capabilities, physician leadership, and advanced product development resources. The strategic move is designed to strengthen YNS’s long-term growth while preserving the trusted formulations and customer-focused philosophy that have made the brand a favorite among skincare consumers. By combining pharmaceutical science with clinical expertise, Trilogy Laboratories aims to accelerate innovation in medical-grade skincare, improve product development, and expand educational resources without compromising the simplicity that defines the YNS product portfolio. The acquisition reflects a broader trend within the cosmeceutical industry, where scientific research, quality manufacturing, and physician-guided product development are increasingly shaping the future of skincare innovation.
Pharmaceutical Expertise Strengthens YNS Cosmeceuticals
The acquisition introduces pharmaceutical formulation science and physician-led innovation into the next phase of YNS Cosmeceuticals’ growth. Trilogy Laboratories is led by Dr. Kristen Flaharty, a pharmaceutical scientist with extensive experience in prescription drug development, formulation science, ingredient optimization, and product commercialization. Supporting product innovation is Dr. Patrick Flaharty, a board-certified physician and dual fellowship-trained facial cosmetic surgeon whose decades of clinical experience treating facial aging and skin health provide valuable insight into future skincare development.
Together, their combined scientific and medical expertise will guide research, formulation improvements, and new product innovation while maintaining the quality and effectiveness that existing customers expect. Trilogy emphasized that the current Power Trio product line, consisting of Cell-Tight, Infusion O2, and Radiance, will remain the foundation of the YNS brand, ensuring continuity while benefiting from enhanced scientific resources and rigorous product evaluation.
FDA-Registered Manufacturing Supports Product Quality
Advertisement
A key advantage of the acquisition is Trilogy Laboratories’ FDA-registered cosmetic manufacturing facility, where products are developed and manufactured under comprehensive quality management systems. The company’s capabilities include formulation development, manufacturing, quality assurance, regulatory oversight, stability testing, and product innovation for physician practices, medical spas, and skincare brands across the United States. By integrating these manufacturing resources into YNS Cosmeceuticals, Trilogy aims to strengthen product consistency, manufacturing efficiency, and regulatory compliance while supporting future expansion.
The company also plans to invest in expanded educational initiatives, digital engagement, scientific research, and carefully developed product innovations that complement YNS’s existing skincare philosophy rather than introducing unnecessary complexity. This science-driven approach reinforces consumer confidence while positioning the brand for sustainable long-term growth in the competitive aesthetics and skincare market.
Strategic Acquisition Advances Cosmeceutical Innovation
The acquisition represents an important milestone for both organizations as Trilogy Laboratories expands its presence within the growing cosmeceutical and regenerative skincare industry. By combining pharmaceutical formulation expertise, clinical leadership, and FDA-registered manufacturing infrastructure with an established consumer skincare brand, Trilogy is creating a stronger platform for future innovation focused on scientifically validated skincare solutions. The transaction reflects increasing industry demand for products supported by pharmaceutical development principles, advanced ingredient science, optimized delivery technologies, and physician-guided formulation strategies.
Rather than significantly changing the YNS product portfolio, Trilogy’s long-term strategy centers on preserving the brand’s trusted identity while enhancing product quality through ongoing research and evidence-based innovation. As consumers continue seeking high-performance skincare backed by science, the acquisition positions both companies to deliver advanced cosmetic products that combine clinical expertise, manufacturing excellence, and simple, effective skincare solutions designed to promote healthier, more resilient skin.
Source: Trilogy Laboratories, YNS Cosmeceuticals press release
